Verdiva Bio vs Profluent Bio

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (36 vs 37)
Verdiva Bio logo

Verdiva Bio

EmergingBioTech

Metabolic Disease

Verdiva Bio raised $200M in 2025 for next-generation oral GLP-1 receptor agonists designed to match injectable semaglutide efficacy with once-daily oral dosing for obesity and type 2 diabetes.

AI VisibilityBeta
Overall Score
D36
Category Rank
#1 of 1
AI Consensus
57%
Trend
up
Per Platform
ChatGPT
40
Perplexity
47
Gemini
29

About

Verdiva Bio is developing oral small molecule GLP-1 receptor agonists to compete in the massive weight loss and diabetes market dominated by injectable semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Current oral GLP-1 options like semaglutide tablets have low bioavailability and require fasting, while Verdiva's chemical series aims for significantly higher exposure matching injectable efficacy with a convenient once-daily pill taken without dietary restrictions.

Full profile
Profluent Bio logo

Profluent Bio

EmergingBiotechnology

AI Protein Design

AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space beyond what evolution has produced.

AI VisibilityBeta
Overall Score
D37
Category Rank
#1 of 1
AI Consensus
69%
Trend
up
Per Platform
ChatGPT
45
Perplexity
35
Gemini
38

About

Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generative models on biological sequence data to design novel proteins with specific structural and functional properties, analogous to how large language models generate text. Profluent made scientific history in 2024 by publishing OpenCRISPR-1, the first gene editor designed entirely by AI rather than adapted from natural organisms, which the company released open source for non-commercial research. The platform enables design of novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space far beyond what evolution has produced. Profluent works with pharmaceutical and agricultural biotechnology companies that need custom protein tools for research and therapeutic development. The company represents a fundamental advance in moving protein engineering from directed evolution and rational design toward generative AI-driven discovery.

Full profile

AI Visibility Head-to-Head

36
Overall Score
37
#1
Category Rank
#1
57
AI Consensus
69
up
Trend
up
40
ChatGPT
45
47
Perplexity
35
29
Gemini
38
46
Claude
37
42
Grok
31

Key Details

Category
Metabolic Disease
AI Protein Design
Tier
Emerging
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Verdiva Bio
Metabolic Disease
Only Profluent Bio
AI Protein Design

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.